News
The deal was Novo Nordisk’s bid to grab back market share from the cheaper, knockoff versions that Hims & Hers and other ...
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...
Earnings season marches on, with quarterly results from Berkshire Hathaway, Palantir and McDonald’s among the highlights over ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...
3don MSNOpinion
Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, ...
2dOpinion
Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.
Novo Nordisk downgraded to Buy amid guidance cuts & competition. Explore its long-term obesity drug potential, strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback